Nyxoah Secures $27 Million for U.S. Market Expansion

Nyxoah (NYXH) has released an update.

Nyxoah SA, a medical technology company, has raised $27 million by selling 3 million shares in an on-the-market offering, with the support of a new American healthcare investor. This financial boost aims to strengthen the company’s focus on the U.S. market, following encouraging data from their DREAM pivotal study and preparations for the U.S. launch of their Genio system for obstructive sleep apnea treatment. Nyxoah’s Genio device, already CE marked in Europe, is making strides towards FDA approval and U.S. commercialization.

For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.